SAN FRANCISCO, March 10, 2017 -- Hagens Berman Sobol Shapiro LLP alerts investors in NantHealth, Inc. (NASDAQ:NH) to the IPO-related securities class action pending in the U.S. District Court for the Central District of California and to the May 6, 2017 Lead Plaintiff deadline.
If you purchased or otherwise acquired securities of NH (1) pursuant and/or traceable to the Company’s registration statement and prospectus issued in connection with the Company’s initial public offering on or about June 1, 2016, or (2) between June 1, 2016 and March 6, 2017 and suffered over $50,000 in losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/NH
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
On March 6, 2017, STATnews published a report entitled “How the world’s richest doctor gave away millions – then steered the cash back to his company.” The report stated that the NantHealth’s founder Patrick Soon-Shiong (“Dr. Soon”) made a $12 million gift to the University of Utah that required the University to spend $10 million for NantHealth’s genetic sequencing work.
The report also stated: “[T]he deal made it possible for [NantHealth] to inflate, by more than 50 percent, the number of test orders it reported to investors late last year while updating them on interest in a flagship product, a diagnostic tool known as GPS Cancer. Soon-Shiong’s team counted genetic sequencing ordered by the University of Utah in those order numbers – even though the work for the university did not have anything to do with diagnosing or recommending treatments for cancer patients.”
This news drove the price of NantHealth shares down approximately 23% to close at $5.50 per share on March 6, 2017.
“We’re focused on management’s earlier tally given to investors in comparison to the recent news that, if true, would appear to contradict those statements,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding NantHealth should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000


Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Washington Post Publisher Will Lewis Steps Down After Layoffs
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 



